4.8 Article

Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype

Journal

NATURE BIOTECHNOLOGY
Volume 32, Issue 6, Pages 551-553

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.2884

Keywords

-

Funding

  1. National Cancer Institute [2-PO1-CA42063, P30-CA14051]
  2. National Institutes of Health (NIH) [R01-CA133404]
  3. Howard Hughes Investigator
  4. NIH Centers for Cancer Nanotechnology Excellence and the Harvard-MIT Center of Cancer Nanotechnology Excellence [5-U51-CA151884-04]
  5. Damon Runyon Fellow [DRG2117- 12]
  6. [1K99CA169512]

Ask authors/readers for more resources

We demonstrate CRISPR-Cas9-mediated correction of a Fah mutation in hepatocytes in a mouse model of the human disease hereditary tyrosinemia. Delivery of components of the CRISPR-Cas9 system by hydrodynamic injection resulted in initial expression of the wild-type Fah protein in similar to 1/250 liver cells. Expansion of Fah-positive hepatocytes rescued the body weight loss phenotype. Our study indicates that CRISPR-Cas9-mediated genome editing is possible in adult animals and has potential for correction of human genetic diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available